The present invention aims to provide a method for producing a microneedle device comprising a coating comprising dexmedetomidine and isoproterenol, in which the stability of isoproterenol during production and after production of the microneedle device is high. A method for producing a microneedle device according to one embodiment of the present invention comprises coating microneedles with a coating liquid to form a coating on the microneedles. The microneedle device comprises a substrate, microneedles disposed on the substrate, and a coating formed on the microneedles. The coating liquid comprises dexmedetomidine or a pharmaceutically acceptable salt thereof, isoproterenol or a pharmaceutically acceptable salt thereof, ethylenediaminetetraacetic acid or a pharmaceutically acceptable salt thereof, and a sulfated polysaccharide.

The present invention relates to the field of cancer therapy. In particular, the present invention relates to a method of preventing, treating or inhibiting the development of tumours and/or metastases in a subject by administering one or more immunomodulators into the skin via a microneedle device.

A wearable device 100 for managing alcohol-driven violence is disclosed. The device 100 comprises a capsule C1 adapted to sense sweat of wearer and detect a level of alcohol in the sweat, a capsule C3 adapted to convert a data detected by the capsule C1 to generate signal activating a capsule C4, a capsule C2 adapted to provide power to the capsule C3, and a capsule C5 adapted to detect a muscle activity of the wearer, wherein the capsule C4 is adapted to inject a drug into the body of the wearer, when activated, and wherein the capsule C5 alerts authorities when no muscle activity is detected.

The present disclosure relates to a method for manufacturing a microneedle containing a coating part on a needle tip and an apparatus used for the method. When a microneedle is manufactured using the coating method and apparatus according to the present disclosure, a coating part in which a target material is impregnated can be easily inserted into skin and effective dissolution is possible. Further, the target material is allowed to show excellent skin permeability with the dissolution of the coating part of the microneedle manufactured according to the present disclosure, thereby a quantitative amount of target material can be effectively delivered into the skin.

An application device for a fluid delivery includes a housing having a bore extending from a bottom of the housing. The bore is sized and shaped for receiving at least a portion of the fluid delivery apparatus. The application device also includes an impact component for impacting the fluid delivery apparatus and moving at least a portion of the fluid delivery apparatus towards a user's skin. The application device includes a safety arm that is positionable relative to the impact component between a locked configuration in which the impact component is secured in a safety position, and a released configuration in which the impact component is free to move within the housing for impacting the fluid delivery apparatus.

The present invention relates to a skin administration system capable of improving the efficiency of skin delivery of an ingredient for controlling release of neurotransmitters and, particularly, to a microneedle containing an ingredient for controlling release of neurotransmitters.

A cold atmospheric plasma (CAP)-mediated ICB therapy/delivery device are disclosed herein that employs a patch having microneedles that are used to deliver the CAP transdermally along with an immune checkpoint inhibitor for enhancing transdermal treatment efficacy. The hollow-structured microneedle patch can facilitate the transportation of CAP through the skin, causing tumor cell death. The release of cancer antigens then promotes the maturation of dendritic cells in the tumor-draining lymph nodes, subsequently initiating the T cell-mediated immune response. Anti-PDL1 antibody (aPDL1), an immune checkpoint inhibitor (or other immune checkpoint inhibitors), released from the microneedle patch (in some embodiments) further augments the anti-tumor immunity. The transdermal combinational CAP and ICB therapy inhibits tumor growth for both primary tumors as well as distant tumors, with prolonged survival in the tumor-bearing mice. Such results should translate to other species.

Disclosed is a microneedling device and a method for the microneedling of human or animal tissue. The method comprises the following steps; (a) providing a microneedling device having an electrically conductive microneedle and an electrically conducting nosepiece assembly spaced apart from the electrically conductive microneedle and acting as a counter electrode; (b) placing the electrically conductive microneedle and nosepiece assembly into contact with the tissue to be microneedled; (c) measuring the electrical impedance between the microneedle tip and the nosepiece or the current through the microneedle motor; (d) commencing insertion of the microneedle and moving the microneedle toward the tissue surface; (e) starting a step counter when the impedance reduces or the microneedle motor current increases; (f) incrementing the step counter with every step of the vertical drive motor until the step count reaches the prespecified value thereby controlling the depth of the hole microneedled.

The present invention provides for microneedle arrays and related systems and methods. Particularly, microneedle arrays that are configured to deliver active agents, including nucleic acids and vaccines, are provided. Additional related methods of vaccinating and minimizing the amount of vaccine necessary for effective inoculation are also provided.

An applicator and method for applying a microneedle device to a skin surface. The applicator can include a first portion comprising a microneedle array, and a second portion coupled to the first portion via a connector. The connector can be configured to yield or fracture by changing from a first state in which the connector is intact to a second state in which the connector is yielded or fractured when a threshold application force is applied to at least one of the first portion and the second portion in a direction substantially perpendicular with respect to the first portion. The method can include pressing the applicator in a direction substantially perpendicular to the first portion to press the microneedle array into the skin surface until the threshold application force is met or exceeded and the connector is changed to its second state.